Image may be NSFW.
Clik here to view.
Clik here to view.
Tocagen fails Phase 3 trial in recurrent brain cancer
Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall...
View Article
More Pages to Explore .....
